{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "DKK", "exchange": "CPH", "shortName": "Genmab A/S", "longName": "Genmab A/S", "messageBoardId": "finmb_665704", "exchangeTimezoneName": "Europe/Copenhagen", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dk_market", "esgPopulated": false, "marketState": "POSTPOST", "epsTrailingTwelveMonths": 83.36, "epsForward": 89.95, "epsCurrentYear": 65.83, "priceEpsCurrentYear": 43.58195, "sharesOutstanding": 65222500, "bookValue": 419.769, "fiftyDayAverage": 2650.1, "fiftyDayAverageChange": 218.8999, "fiftyDayAverageChangePercent": 0.082600616, "twoHundredDayAverage": 2776.875, "twoHundredDayAverageChange": 92.125, "twoHundredDayAverageChangePercent": 0.03317578, "marketCap": 187123351552, "forwardPE": 31.895498, "priceToBook": 6.834711, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.6 - Hold", "firstTradeDateMilliseconds": 972025200000, "priceHint": 2, "regularMarketChangePercent": 0.0, "regularMarketPrice": 2869.0, "regularMarketChange": 0.0, "regularMarketTime": 1683903572, "regularMarketDayHigh": 2878.0, "regularMarketDayRange": "2801.0 - 2878.0", "regularMarketDayLow": 2801.0, "regularMarketVolume": 89633, "regularMarketPreviousClose": 2869.0, "bid": 2867.0, "ask": 2869.0, "fullExchangeName": "Copenhagen", "financialCurrency": "DKK", "regularMarketOpen": 2825.0, "averageDailyVolume3Month": 101487, "averageDailyVolume10Day": 80817, "fiftyTwoWeekLowChange": 1006.0, "fiftyTwoWeekLowChangePercent": 0.5399893, "fiftyTwoWeekRange": "1863.0 - 3327.0", "fiftyTwoWeekHighChange": -458.0, "fiftyTwoWeekHighChangePercent": -0.13766156, "fiftyTwoWeekLow": 1863.0, "fiftyTwoWeekHigh": 3327.0, "earningsTimestamp": 1691071200, "earningsTimestampStart": 1691071200, "earningsTimestampEnd": 1691071200, "trailingAnnualDividendRate": 0.0, "trailingPE": 34.416985, "trailingAnnualDividendYield": 0.0, "tradeable": false, "cryptoTradeable": false, "symbol": "GMAB.CO"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Kalvebod Brygge 43", "city": "Copenhagen", "zip": "1560", "country": "Denmark", "phone": "45 70 20 27 28", "website": "https://www.genmab.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.", "fullTimeEmployees": 1660, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jan G.J. van de Winkel Ph.D.", "age": 61, "title": "Co-Founder, Pres & CEO", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 18800000, "fmt": "18.8M", "longFmt": "18,800,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Anthony  Pagano", "age": 44, "title": "Exec. VP & CFO", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 7000000, "fmt": "7M", "longFmt": "7,000,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Anthony  Mancini", "age": 51, "title": "Exec. VP & COO", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 7600000, "fmt": "7.6M", "longFmt": "7,600,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Martin  Schultz", "age": 46, "title": "Sr. Director of Clinical Operations  & Non-Independent Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 500000, "fmt": "500k", "longFmt": "500,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Judith V. Klimovsky M.D.", "age": 64, "title": "Exec. VP & Chief Devel. Officer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 7900000, "fmt": "7.9M", "longFmt": "7,900,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Tahamtan  Ahmadi", "age": 49, "title": "Exec. VP, Chief Medical Officer & Head of Experimental Medicines", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 7500000, "fmt": "7.5M", "longFmt": "7,500,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mijke  Zachariasse Ph.D.", "age": 48, "title": "Sr. Director, Head of Antibody Research Materials & Non-Independent Director", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 1000000, "fmt": "1M", "longFmt": "1,000,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Takahiro  Hamatani", "age": 47, "title": "Sr. Director of Fin. Japan & Non-Independent Director", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 500000, "fmt": "500k", "longFmt": "500,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Andrew  Carlsen", "title": "Sr. Director, VP & Head of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Birgitte  Stephensen M.Sc.", "age": 61, "title": "Exec. VP & Chief Legal Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 2, "boardRisk": 1, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 1, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}